#USA #San Diego #Crenessity #Neurocrine #INGREZZA

Neurocrine Biosciences Reports Strong Q2 2026 Financial Results

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has made headlines with its recent financial results for the second quarter of 2026, which ended on June 30. The company posted a remarkable total revenue of $959 million, marking a significant 39% increase from the $688 million reported in the same quarter of the previous year. This growth is attributed to the expansion of its commercial portfolio, particularly highlighted by the success in sales of its flagship product, INGREZZA® (valbenazine).

Key Highlights of Q2 2026

CEO Kyle W. Gano, Ph.D., expressed confidence in the company's strategy, noting that the results reflect a plan designed to produce sustainable growth. The company reported net product sales for INGREZZA at $716 million, which reflects a 15% year-over-year increase. Similarly, CRENESSITY® (crinecerfont) saw an astonishing 247% growth in sales, amounting to $184 million, driven by strong patient demand and favorable reimbursement rates.

Furthermore, Neurocrine's latest acquisition of Soleno Therapeutics has strengthened its position in the endocrinology sector. The acquisition was finalized in May 2026, bringing in the first-in-class therapy VYKAT® (diazoxide choline) XR, which contributed $54 million in net product sales within just a few weeks post-acquisition. Overall, the pro-forma revenue was estimated at $998 million when including VYKAT XR sales for the full quarter.

Continued Focus on Innovations

Neurocrine's commitment to advancing its research and development pipeline remains a priority. The second quarter saw increased R&D expenditures, tallying at $327 million. This investment supports late-stage product development, including the upcoming Phase 3 clinical trials for osavampator, aimed at treating major depressive disorder, and direclidine for schizophrenia. Both trials are set to bear significant results in 2027, further emphasizing Neurocrine’s focus on addressing unmet medical needs.

Future Guidance and Strategic Goals

In light of the Q2 performance, Neurocrine Biosciences has raised its full-year guidance for INGREZZA, now expecting net product sales between $2.825 billion and $2.875 billion. This adjustment reflects the company’s optimism regarding continued sales growth driven by increasing prescription volumes. The firm also reported an increase in total cash, cash equivalents, and marketable securities, amounting to approximately $482 million, establishing a solid financial foundation for future endeavors.

Clinical Milestones and Key Investments

Recent clinical developments are promising, including two-year data from the Phase 3 CAHtalyst® studies, which demonstrated positive patient outcomes. Notably, the Pediatric study showed significant growth outcomes in children with classic congenital adrenal hyperplasia. These results not only highlight the effectiveness of CRENESSITY but also showcase Neurocrine's commitment to addressing complex health conditions.

Moreover, the company has promoted Samir Siddhanti to the Chief Business Officer position, a strategic move intended to bolster business development and corporate strategies in alignment with Neurocrine’s growth targets.

Conclusion

Neurocrine Biosciences is establishing its dominance in the biotechnology landscape through strategic investments and a growing portfolio of innovative therapies. With a strong financial performance in Q2 2026, continued focus on research and development, and upcoming clinical milestones, the company is well-positioned to make enduring contributions to patient care and improve shareholder value. As they embark on this promising trajectory, stakeholders and investors alike will be closely watching Neurocrine's advancements in the biomedical field.

For more updates, tune into their live conference call and webcast held on July 30, 2026, and access the detailed financial documentation available on Neurocrine Biosciences' official website.